Clinical Trial Update: RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy [Phase 2]

View source ↗

Summary

Phase II trial evaluating pembrolizumab plus low-dose radiotherapy for relapsed/refractory non-Hodgkin lymphoma; the study is listed as active but not currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Non Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING